BeOne Medicines Ltd ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
73.4%projected annual EPS growth
Analyst Coverage
27analysts covering
FY Revenue (est.)
$6.8Bnext fiscal year
FY EPS (est.)
$7.60next fiscal year
Monitoring Framework
Key Performance Indicators
BRUKINSA Global Revenue Quarterly1.1BTarget: Continued double-digit volume growth and market share expansion in BTK inhibitor indications
Total Product Revenue Quarterly1.5BTarget: Full-year 2026 revenue guidance of $6.3 billion to $6.5 billion
GAAP Operating Income AnnuallyTarget: Full-year 2026 guidance of $750 million to $850 million
Watch Items
- BRUKINSA Frontline Mantle Cell Lymphoma (MCL) Phase 3 Data and Regulatory FilingsTrigger: FDA and global regulatory submissions/approvalsAction: Monitor regulatory timelines and commercial launch preparation for frontline MCL
- Hopewell, New Jersey Manufacturing Facility ExpansionTrigger: Completion of the $300 million expansion phaseAction: Track construction milestones and operational readiness for clinical and commercial biologics production
- Solid Tumor Pipeline Progress (e.g., TEVIMBRA and early-stage assets)Trigger: Phase 3 trial readouts and clinical data presentations at major medical congressesAction: Evaluate clinical efficacy/safety profiles and potential market entry strategies
Research as of 2 Sep 2026